Show simple item record

dc.contributor.authorO, Michelle L.
dc.contributor.authorMorrow, David Andrew
dc.contributor.authorTsimikas, Sotirios
dc.contributor.authorSloan, Sarah
dc.contributor.authorRen, Angela F.
dc.contributor.authorHoffman, Elaine
dc.contributor.authorDesai, Nihar R.
dc.contributor.authorSolomon, Scott David
dc.contributor.authorDomanski, Michael
dc.contributor.authorArai, Kiyohito
dc.contributor.authorChiuve, Stephanie Elizabeth
dc.contributor.authorCannon, Christopher Paul
dc.contributor.authorSacks, Frank Martin
dc.contributor.authorSabatine, Marc Steven
dc.date.accessioned2017-02-07T22:15:59Z
dc.date.issued2014
dc.identifier.citationO’Donoghue, Michelle L., David A. Morrow, Sotirios Tsimikas, Sarah Sloan, Angela F. Ren, Elaine B. Hoffman, Nihar R. Desai, et al. 2014. “Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease.” Journal of the American College of Cardiology 63 (6) (February): 520–527. doi:10.1016/j.jacc.2013.09.042.en_US
dc.identifier.issn0735-1097en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:30205718
dc.description.abstractOBJECTIVES: The purpose of this study was to assess the prognostic utility of lipoprotein(a) [Lp(a)] in individuals with coronary artery disease (CAD). BACKGROUND: Data regarding an association between Lp(a) and cardiovascular (CV) risk in secondary prevention populations are sparse. METHODS: Plasma Lp(a) was measured in 6,708 subjects with CAD from 3 studies; data were then combined with 8 previously published studies for a total of 18,978 subjects. RESULTS: Across the 3 studies, increasing levels of Lp(a) were not associated with the risk of CV events when modeled as a continuous variable (odds ratio [OR]: 1.03 per log-transformed SD, 95% confidence interval [CI]: 0.96 to 1.11) or by quintile (Q5:Q1 OR: 1.05, 95% CI: 0.83 to 1.34). When data were combined with previously published studies of Lp(a) in secondary prevention, subjects with Lp(a) levels in the highest quantile were at increased risk of CV events (OR: 1.40, 95% CI: 1.15 to 1.71), but with significant between-study heterogeneity (p = 0.001). When stratified on the basis of low-density lipoprotein (LDL) cholesterol, the association between Lp(a) and CV events was significant in studies in which average LDL cholesterol was ≥130 mg/dl (OR: 1.46, 95% CI: 1.23 to 1.73, p < 0.001), whereas this relationship did not achieve statistical significance for studies with an average LDL cholesterol <130 mg/dl (OR: 1.20, 95% CI: 0.90 to 1.60, p = 0.21). CONCLUSIONS: Lp(a) is significantly associated with the risk of CV events in patients with established CAD; however, there exists marked heterogeneity across trials. In particular, the prognostic value of Lp(a) in patients with low cholesterol levels remains unclear.en_US
dc.language.isoen_USen_US
dc.publisherElsevier BVen_US
dc.relation.isversionofdoi:10.1016/j.jacc.2013.09.042en_US
dc.relation.hasversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3945105/en_US
dash.licenseLAA
dc.subjectbiomarkersen_US
dc.subjectlipoprotein(a)en_US
dc.subjectrisk stratificationen_US
dc.subjectsecondary preventionen_US
dc.titleLipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Diseaseen_US
dc.typeJournal Articleen_US
dc.description.versionAccepted Manuscripten_US
dc.relation.journalJournal of the American College of Cardiologyen_US
dash.depositing.authorSacks, Frank Martin
dc.date.available2017-02-07T22:15:59Z
dc.identifier.doi10.1016/j.jacc.2013.09.042*
dash.authorsorderedfalse
dash.contributor.affiliatedHoffman, Elaine Borland
dash.contributor.affiliatedMorrow, David
dash.contributor.affiliatedChiuve, Stephanie
dash.contributor.affiliatedSolomon, Scott
dash.contributor.affiliatedSabatine, Marc
dash.contributor.affiliatedCannon, Christopher
dash.contributor.affiliatedSacks, Frank


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record